Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

28 Feb 2022

Abstract excerpt

The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from five observational cohorts recruiting ICI-naive patients with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Gut microbiota and health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35228751
DOI: 10.1038/s41591-022-01695-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaPMID 35228751Read ↗

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanomaSemantic proximity Read ↗

Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanomaSemantic proximity Read ↗

Taxonomy-free fecal microbiome profiles enable robust prediction of immunotherapy response and toxicity in melanomaSemantic proximity Read ↗

Gut microbiome is associated with recurrence-free survival in patients with resected Stage IIIB-D or Stage IV melanoma treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Microbiome influencers of checkpoint blockade–associated toxicitySemantic proximity Read ↗

A gut microbial signature for combination immune checkpoint blockade across cancer typesSemantic proximity Read ↗

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patientsSemantic proximity Read ↗

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeSemantic proximity Read ↗

The gut microbiome and melanoma: A reviewSemantic proximity Read ↗

Melanoma and microbiota: Current understanding and future directionsSemantic proximity Read ↗

Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway InhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.